Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Omburtamab I-124 |
Synonyms | |
Therapy Description |
Omburtamab I-124 is a B7-H3 (CD276) glycoprotein targeting monoclonal antibody radiolabeled with Iodine 124, which has potential antitumor activity against CD276-expressing tumor cells (PMID: 31405921; J Clin Oncol. 37, no. 15_suppl). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Omburtamab I-124 | Iodine I 124 Omburtamab|Iodine I 124 MOAB 8H9 | CD276 Antibody 16 | Omburtamab I-124 is a B7-H3 (CD276) glycoprotein targeting monoclonal antibody radiolabeled with Iodine 124, which has potential antitumor activity against CD276-expressing tumor cells (PMID: 31405921; J Clin Oncol. 37, no. 15_suppl). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01502917 | Phase I | Omburtamab I-124 | Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy | Completed | USA | 0 |